|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||31.91 - 32.05|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||21.87|
|Dividend & Yield||1.03 (3.23%)|
|1y Target Est||N/A|
The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.
Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.
Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.